Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging

PurposeWe evaluated whether the addition of delayed phase imaging (DPI) gadobenate dimeglumine-enhanced MRI to dynamic postcontrast imaging improves the characterization of small hepatocellular carcinoma (HCC) and the differentiation between HCC, high grade dysplastic nodules (HGDN), and low grade dysplastic nodules (LGDN).MethodsTwenty-five cirrhotic patients with 30 nodules (16 HCC, 8 HGDNs, and 6 LGDNs; maximum size of 3 cm) were included in this retrospective study. The diagnostic reference standard was histology. All the patients underwent MRI both prior to and following intravenous administration of gadobenate dimeglumine. The lesions were classified as hypointense, isointense, hyperintense on DPI for qualitative assessment. In the quantitative analysis the relative tumor-liver contrast to noise ratio (CNR) of the lesions on DPI was calculated.ResultsAll HCCs were hypointense on DPI while only 8 (57.1%) of 14 DNs were hypointense and only 1 of 6 (16.6%) LGDNs was hypointense. There was a statistically significant difference in the hypointensity on DPI between HCCs and DNs (p = 0.003) in the qualitative analysis but not in the CNR values while there was a strong statistically significant difference in the hypointensity on DPI in the qualitative (p = 0.00001) and quantitative analysis (p < 0.05) between LGDNs and the group obtained by unifying HGDNs and HCCs.ConclusionDPI is helpful in differentiating HCCs and HGDNs from LGDNs. Demonstration of hypointensity on DPI should raise the suspicion of HGDN or hypovascular HCC in the case of nodules with atypical dynamic pattern.

[1]  M. Roncalli,et al.  Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. , 2003, Journal of hepatology.

[2]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[3]  R. Manfredi,et al.  Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd‐BOPTA) , 1999, Journal of magnetic resonance imaging : JMRI.

[4]  Jae Young Lee,et al.  The Value of Gadobenate Dimeglumine-Enhanced Delayed Phase MR Imaging for Characterization of Hepatocellular Nodules in the Cirrhotic Liver , 2008, Investigative radiology.

[5]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[6]  A. Giovagnoni,et al.  Detection of Malignant Primary Hepatic Neoplasms with Gadobenate Dimeglumine (Gd-BOPTA) Enhanced T1-Weighted Hepatocyte Phase MR Imaging: Results of Off-site Blinded Review in a Phase-II Multicenter Trial , 2001, Korean journal of radiology.

[7]  Osamu Matsui,et al.  Imaging of Multistep Human Hepatocarcinogenesis by CT during Intra-Arterial Contrast Injection , 2004, Intervirology.

[8]  O. Matsui,et al.  Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. , 1991, Radiology.

[9]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[10]  Y. N. Park,et al.  Dysplastic nodules and hepatocarcinogenesis. , 2002, Clinics in liver disease.

[11]  S. Hussain,et al.  Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. , 2002, Radiographics : a review publication of the Radiological Society of North America, Inc.

[12]  HCC Diagnosis with Liver-Specific MRI – Close to Histopathology , 2009, Digestive Diseases.

[13]  E. Rummeny,et al.  Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. , 2000, AJR. American journal of roentgenology.

[14]  I. Wanless,et al.  Terminology of nodular hepatocellular lesions , 1995 .

[15]  L. Jacks,et al.  Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. , 2011, Radiology.

[16]  C. Bartolozzi,et al.  Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR , 2011, Abdominal Imaging.

[17]  Young Kon Kim,et al.  Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions , 2004, European Radiology.

[18]  F. Akisik,et al.  Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? , 2011, Clinical radiology.

[19]  O. Matsui,et al.  Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis , 2011, Abdominal Imaging.

[20]  A. Spinazzi,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[21]  H. Popper.  American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .

[22]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[23]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[24]  J. Willatt,et al.  MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.

[25]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[26]  N. Faccioli,et al.  Solid Hypervascular Liver Lesions: Accurate Identification of True Benign Lesions on Enhanced Dynamic and Hepatobiliary Phase Magnetic Resonance Imaging After Gadobenate Dimeglumine Administration , 2011, Investigative radiology.

[27]  Yoshiyuki Suzuki,et al.  Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis , 2006, Cancer.

[28]  G. Morana,et al.  Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application. , 1996, Radiology.

[29]  Singal Amit,et al.  Screening for hepatocellular carcinoma. , 2008, Gastroenterology & hepatology.

[30]  H. Uchino,et al.  DEPARTMENT OF INTERNAL MEDICINE , 1966 .